TITLE

Combination Therapy With Octreotide and α-Interferon: Effect on Tumor Growth in Metastatic Endocrine Gastroenteropancreatic Tumors

AUTHOR(S)
Frank, Margareta; Klose, Klaus J.; Wied, Matthias; Ishaque, Natascha; Schade-Brittinger, Carmen; Arnold, Rudolf
PUB. DATE
May 1999
SOURCE
American Journal of Gastroenterology;May1999, Vol. 94 Issue 5, p1381
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: We investigated the antiproliferative efficacy of the addition of a-interferon to the somatostatin analogue octreotide in patients with metastasized gastroenteropancreatic tumors unresponsive to octreotide monotherapy. METHODS: In an open prospective trial, 21 patients with metastasized neuroendocrine gastroenteropancreatic tumors (nine patients with carcinoid syndrome, eight with nonfunctioning tumors, four with gastrinoma) were treated with 5 x 106 IU α-interferon tiw in addition to 200 µg of octreotide tid. All patients, including 16 patients with preceding monotherapy with 200 µg of octreotide tid, had tumor progression documented by computed tomography before entering the study. Growth response (computed tomography documented) and biochemical response were assessed at 3-month intervals. RESULTS: Inhibition of tumor growth was observed in 14 patients (67%), 11 of whom had preceding octreotide monotherapy; complete regression was observed in one patient lasting for 49 months and stable disease (stand-still) in 13 patients lasting for 3 to 52 months (median, 12 months). Seven patients failing this combination therapy exhibited a significantly shorter overall survival (median, 23 months: range, 5 to 42 months) than the 14 patients responding to this regimen (median, 68 months; range, 12 to 112 months; p = 0.007). Two patients are still alive. Biochemical response was achieved in 69% of patients with functioning tumors: in three of four patients with gastrinoma and in six of nine patients with carcinoid syndrome. CONCLUSIONS: These data suggest that the addition of a-interferon to octreotide has antiproliferative efficacy in a subgroup of patients with advanced metastatic disease unresponsive to octreotide monotherapy. Prolonged survival was seen in the responder group.
ACCESSION #
16070912

 

Related Articles

  • ACUTE LIVER INJURY AND OCTREOTIDE. González-Martin, J. A.; Donnay, S.; Morillas, J.; Gómez-Aparicio, C.; Garcia-Cano, J.; Pérez-Vigara, G.; Roldá, A. // American Journal of Gastroenterology;Nov1996, Vol. 91 Issue 11, p2434 

    Octreotide is a synthetic analogue of somatostatin with therapeutic applications in a variety of endocrine and gastrointestinal disorders. We report a patient with acromegaly who developed acute hepatocellular liver injury after receiving two O.1-mg doses of octreotide. The drug causality was...

  • Management of bronchial carcinoid: An anaesthetic challenge. Gupta, Prasoon; Kaur, Ranvinder; Chaudhary, Lalita; Jain, Aruna // Indian Journal of Anaesthesia;Mar/Apr2014, Vol. 58 Issue 2, p202 

    Carcinoid tumours pose a great challenge to anaesthesiologist, especially if carcinoid syndrome is present. We report peri-operative management of a patient with carcinoid syndrome who underwent upper lobectomy. Pre-operative optimisation for 10 days before surgery with injection octreotide and...

  • A Single-Centre Experience with Octreotide in the Treatment of Different Hypersecretory Syndromes in Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors. Berković, Maja Cigrovski; Altabas, Velimir; Herman, Davorka; Hrabar, Davor; Goldoni, Vesna; Vizner, Branka; Zjačić-Rotkvić, Vanja // Collegium Antropologicum;Jun2007, Vol. 31 Issue 2, p531 

    The aim of this research was to assess the clinical and biochemical efficacy of the octreotide in the treatment of patients with various functional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study included 14 patients treated with octreotide for 6 months. They were diagnosed...

  • USE OF OCTREOTIDE IN THE TREATMENT OF MESENTERIC ANGINA. Anderson, Simon H. C.; Dalton, Harry R. // American Journal of Gastroenterology;Jul1997, Vol. 92 Issue 7, p1222 

    The case of a 57-yr-old man with a medical history or generalized atherosclerotic disease and newly diagnosed intestinal ischemia is presented. Because the patient was a poor surgical and anesthetic risk, medical treatment in the form of octreotide was administered with remarkable symptomatic...

  • An Open Trial of Octreotide Long-Acting Release in the Management of Short Bowel Syndrome. Nehra, Vandana; Camilleri, Michael; Burton, Duane; Oenning, LaVonne; Kelly, Darlene G. // American Journal of Gastroenterology;May2001, Vol. 96 Issue 5, p1494 

    OBJECTIVES: The aim of this study was to assess the effects of the long-acting release (LAR) depot octreotide preparation Sandostatin LAR Depot on stool water and electrolyte losses, fecal fat excretion, and GI transit in patients with short bowel syndrome. METHODS: We performed a 15-wk,...

  • Resolution of Musculoskeletal Symptoms in the Carcinoid Syndrome after Treatment with the Somatostatin Analog Octreotide. Smith, Sidney; Anthony, Lowell; Roberts, L. Jackson; Oates, John A.; Pincus, Theodore // Annals of Internal Medicine;1/1/90, Vol. 112 Issue 1, p66 

    Describes three patients with the carcinoid syndrome in whom treatment with octreotide was followed by resolution of their musculoskeletal symptoms. Case reports; Discussion on carcinoid syndrome.

  • Octreotide Acetate Administration for Malignant Bowel Obstruction Induces Severe Bradycardia in Patients with Terminal Stage Cancer: Two Case Reports. Kubota, Kazuko; Hasumi, Yoko; Numata, Aya; Tukazaki, Takehiro; Horie, Koji; Hashimoto, Kouiti; Yokota, Harushige // Journal of Palliative Medicine;Jun2013, Vol. 16 Issue 6, p596 

    The article presents two case studies of a 44-year-old female patient diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IV b cervical cancer and a 61-year-old female diagnosed with FIGO stage II b cervical cancer. It states that both developed bradycardia 6 and 12...

  • 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Capello, Astrid; Krenning, Eric; Bernard, Bert; Reubi, Jean-Claude; Breeman, Wout; de Jong, Marion // European Journal of Nuclear Medicine & Molecular Imaging;Nov2005, Vol. 32 Issue 11, p1288 

    Purpose: Peptide receptor scintigraphy with the radioactive somatostatin analogue 111In-DTPA-octreotide is a sensitive and specific technique to show in vivo the presence of somatostatin receptors on various tumours. Since 111In emits not only gamma rays but also therapeutic Auger and internal...

  • Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. Jia, Wei-Dong; Xu, Ge-Liang; Xu, Rong-Nan; Sun, Hui-Chuan; Wang, Lu; Yu, Ji-Hai; Wang, Jian; Li, Jian-Sheng; Zhai, Zhi-Ming; Xue, Qiong // Journal of Cancer Research & Clinical Oncology;Jun2003, Vol. 129 Issue 6, p327 

    Purpose. To investigate the effect of octreotide on angiogenesis induced by human hepatocellular carcinoma (HCC) and to evaluate whether octreotide can suppress tumor growth in nude mice bearing human HCC xenografts through inhibition of angiogenesis. Methods. Using MTT assay, invasion assay,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics